Avastin Breast Cancer Approval In Spotlight With AVADO
This article was originally published in The Pink Sheet Daily
Executive Summary
CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.
You may also be interested in...
Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer
Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.
Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer
Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.
Avastin/Tarceva Combo Fails In Second-Line NSCLC
Industry analysts see little consequence, as each is already well-positioned in lung cancer.